{
    "root": "c8acbaea-60cc-46d6-9f3f-7b1f53b2410b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "TADALAFIL",
    "value": "20250423",
    "ingredients": [
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TRIACETIN",
            "code": "XHX3C3X673"
        },
        {
            "name": "TADALAFIL",
            "code": "742SXX0ICT"
        }
    ],
    "indications": "Tadalafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 ) If tadalafil tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks ( 1.4 ).",
    "contraindications": "Do not split tadalafil tablets; entire dose should be taken.",
    "warningsAndPrecautions": "Tadalafil tablets USP 2.5 mg are light-orange yellow colored, oval shaped, biconvex beveled edge, film coated tablets with debossing \"A9\" on one side and \"2.5\" on other side.\n                        Bottles of 30                                                   13668-565-30\n                        Bottles of 500                                                 13668-565-05\n                        \n                        Tadalafil tablets USP 5 mg are yellow colored, oval shaped, biconvex beveled edge, film coated tablets with debossing \"B1\" on one side and \"5\" on other side.\n                        Bottles of 30                                                   13668-566-30\n                        Bottles of 500                                                 13668-566-05\n                        \n                        Tadalafil tablets USP 10 mg are yellow colored, oval shaped, biconvex beveled edge, film coated tablets with debossing \"A15\" on one side and \"10\" on other side.\n                        Bottles of 30                                                   13668-567-30\n                        Bottles of 500                                                 13668-567-05\n                        \n                        Tadalafil tablets USP 20 mg are yellow colored, oval shaped, biconvex beveled edge, film coated tablets with debossing \"A16\" on one side and \"20\" on other side.\n                        Bottles of 30                                                   13668-568-30\n                        Bottles of 500                                                 13668-568-05",
    "adverseReactions": "Administration of tadalafil to patients using any form of organic nitrate is contraindicated. Tadalafil was shown to potentiate the hypotensive effect of nitrates ( 4.1 ). History of known serious hypersensitivity reaction to tadalafil or ADCIRCA ® . ( 4.2 ). Administration with guanylate cyclase (GC) stimulators, such as riociguat ( 4.3 )."
}